Last reviewed · How we verify
Pantoprazol
At a glance
| Generic name | Pantoprazol |
|---|---|
| Also known as | no other names |
| Sponsor | Northern Orthopaedic Division, Denmark |
| Target | ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
- Erosive esophagitis
- Gastric Hypersecretory Conditions
- Gastroesophageal reflux disease
- Maintenance of Healing Erosive Esophagitis
- Multiple endocrine adenomas
- Peptic ulcer
- Zollinger-Ellison syndrome
Common side effects
- Upper Respiratory Infection
- Headache
- Fever
- Diarrhea
- Vomiting
- Rash
- Abdominal Pain
- Constipation
- Nausea
- Flatulence
- Allergic Reaction
- Facial Edema
Serious adverse events
- Acute Tubulointerstitial Nephritis
- Clostridium difficile-Associated Diarrhea
- Bone Fracture
- Severe Cutaneous Adverse Reactions
- Cutaneous and Systemic Lupus Erythematosus
- Cyanocobalamin (Vitamin B-12) Deficiency
- Hypomagnesemia and Mineral Metabolism
- Fundic Gland Polyps
Key clinical trials
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor (PHASE2)
- Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients (PHASE2, PHASE3)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs (PHASE4)
- Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years (PHASE2)
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Pharmacokinetics of Clozapine and Norclozapine and the Effect of Pantoprazole (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pantoprazol CI brief — competitive landscape report
- Pantoprazol updates RSS · CI watch RSS
- Northern Orthopaedic Division, Denmark portfolio CI